Lotus Endometriosis Institute is highlighting the heterogeneous nature of endometriosis in light of new reporting on broader symptom profiles, emphasizing why differences in immune, hormonal, and molecular biology may require more individualized approaches to diagnosis and treatment.
-- The Lotus Endometriosis Institute is calling for a more individualized approach to understanding and managing endometriosis following new research coverage examining whether broader symptom patterns may be overlooked in patients with the condition. The Institute emphasizes that endometriosis is not a single, uniform disease. Instead, it is a heterogeneous condition in which biological differences may influence symptoms, disease behavior and response to treatment.
“Endometriosis does not affect every patient in the same way, and we should not expect a single symptom profile or treatment approach to apply to everyone,” said Steven Vasilev, MD, founder of the Lotus Endometriosis Institute. “Understanding the individual patient's symptoms, history, and disease characteristics is essential to developing a care plan that addresses the full picture rather than focusing on one symptom or one aspect of the disease.”
The Institute's position comes as a new report from Medscape examines emerging evidence that endometriosis may present through broader symptom profiles than the pelvic pain and menstrual symptoms traditionally associated with the condition. The report highlights research suggesting that recognizing patterns beyond conventional symptoms could provide clinicians with additional information when evaluating patients.
The Institute's approach reflects the broader scientific understanding that endometriosis can involve biologically distinct subtypes with potentially different origins, clinical behavior and treatment responses. Differences in immune responses, hormone-receptor expression and transcriptomic profiles may help explain why the condition can manifest differently between individuals.
Recent molecular research provides further evidence for this heterogeneity. A 2023 study identified distinct endometriosis subtypes associated with differences in gene expression, stromal composition, immune-cell infiltration, fibrosis and immune responses, noting that treating endometriosis as a single disease phenotype may obscure subtype-specific relationships with risk factors and treatment response.
More recent research published in 2026 has similarly identified divergent immunological and stromal programs between peritoneal and ovarian endometriosis, suggesting that different lesion types may have substantially different biological characteristics.
These findings remain an area of active research and do not establish a clinically validated molecular test for determining an individual's endometriosis subtype. Instead, they add to evidence that the disease may involve different biological pathways and that a one-size-fits-all framework may not fully capture the experiences of all patients.
For patients, the implications extend beyond classification. Symptoms do not necessarily correspond neatly with disease location or severity, and an individual's experience may include combinations of pain, gastrointestinal or urinary symptoms, fertility difficulties, fatigue and other concerns. The World Health Organization notes that symptom variability can contribute to diagnostic difficulty and reports that the average time to diagnosis remains between four and 12 years.
A comprehensive evaluation of symptoms, medical history, imaging, prior treatment and individual circumstances can therefore form an important part of conversations about diagnosis and treatment.
The Lotus Endometriosis Institute encourages healthcare professionals to consider the variability of endometriosis when evaluating patients rather than assuming that a diagnosis represents a uniform biological condition. More information about endometriosis and the Institute's approach to care is available at https://lotusendo.com/condition-endometriosis
About Lotus Endometriosis Institute
The Lotus Endometriosis Institute is a specialized clinical program focused on endometriosis and related conditions. Founded by Steven Vasilev, MD, the Institute provides evaluation and advanced surgical care for patients with complex and recurrent endometriosis.
Contact Info:
Name: Dr. Steven Vasilev
Email: Send Email
Organization: Lotus Endometriosis Institute
Address: 154 Traffic Way, Arroyo Grande, CA 93420, United States
Website: https://lotusendo.com
Source: PressCable
Release ID: 89206821
If there are any problems, discrepancies, or queries related to the content presented in this press release, we kindly ask that you notify us immediately at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team will be available round-the-clock to address your concerns within 8 hours and take necessary actions to rectify any identified issues or support you with press release takedowns. Ensuring accurate and trustworthy information is our unwavering commitment.
